Belsomra Pre-Surgery Hold Window: What Clinicians and Patients Need to Know

Why Suvorexant Requires a Pre-Surgery Hold at All

Suvorexant works by blocking both OX1R and OX2R orexin receptors, effectively silencing the wake-promoting neuropeptide system that keeps patients arousable [1]. That mechanism is exactly what makes the drug useful for insomnia, and exactly what makes it problematic in the perioperative window.

General anesthetics, opioids, and benzodiazepines all suppress arousal through separate but converging pathways. When suvorexant is still pharmacologically active at induction, the orexin system cannot contribute its normal counter-regulatory push toward wakefulness during emergence [2]. The clinical result is deeper-than-expected sedation, delayed emergence, and a narrowed safety margin for airway management.

The Orexin System and Anesthetic Combination

The locus coeruleus, dorsal raphe, and tuberomammillary nucleus all receive excitatory orexin projections [3]. Propofol, sevoflurane, and dexmedetomidine suppress these same nuclei through GABA-A, glycine, and alpha-2 adrenergic mechanisms respectively [4]. Suvorexant pre-loading removes orexin-driven counter-pressure, leaving anesthetic agents with less physiological resistance to overcome. Emergence time lengthens. Airway protective reflexes return more slowly.

Complex Sleep Behaviors as a Perioperative Signal

Herring et al. (Lancet Neurol 2014, N=1,021) demonstrated that suvorexant at 40 mg produced next-morning residual sedation in 9% of patients vs. 3% for placebo (P<0.001) [1]. That residual sedation signal is the same pharmacodynamic liability that concerns anesthesiologists: the drug does not always clear within one dosing cycle, and surgery scheduled within hours of the last dose carries real risk.

Pharmacokinetics That Drive the Hold Duration

Half-Life and Variability

The FDA label lists a mean terminal elimination half-life of 12 hours for suvorexant 20 mg in healthy adults [5]. However, the 90% prediction interval spans roughly 9 to 17 hours across the studied population. Using 5 half-lives as the standard clearance threshold, the range runs from 45 hours (1.9 days) at the fast end to 85 hours (3.5 days) at the slow end [5].

Clinicians rounding up to 5 to 7 days are adding a buffer that accommodates interindividual variability, the slower clearance seen with hepatic impairment, and the compounding effect of CYP3A4 inhibitors commonly prescribed alongside sleep medications.

CYP3A4 Interactions That Extend Effective Half-Life

Suvorexant is metabolized almost entirely by CYP3A4 [5]. Co-administration with moderate CYP3A4 inhibitors such as diltiazem or fluconazole increases suvorexant AUC by approximately 2-fold [5]. Strong inhibitors such as ketoconazole or clarithromycin can raise AUC 3-fold or more [5]. In those patients, a 5-half-life calculation based on the nominal 12-hour half-life will underestimate true tissue exposure. The hold window should extend to 7 to 10 days, or the inhibitor should be stopped first and its own clearance factored in.

A 2021 review of orexin antagonist pharmacology in Pharmacology and Therapeutics confirmed that CYP3A4 inhibition is the dominant source of clinically meaningful suvorexant accumulation [6]. Prescribers reviewing a patient's medication list before surgery should flag any azole antifungal, macrolide antibiotic, or non-dihydropyridine calcium channel blocker as a trigger for extended hold.

Hepatic Impairment Considerations

The FDA label contra-indicates suvorexant in severe hepatic impairment and notes prolonged half-life in moderate impairment [5]. Patients with Child-Pugh B cirrhosis have shown AUC increases of up to 60% in pharmacokinetic studies, effectively extending functional half-life toward 19 hours [5]. For those patients, a 7-day minimum hold is appropriate, with anesthesiology consultation recommended to review baseline sedation risk.

What Published Literature Says About DORA Perioperative Risk

Herring et al. Lancet Neurol 2014

The key Phase 3 trials published by Herring et al. Enrolled 1,021 patients across two parallel studies and tested suvorexant at 15/20 mg and 30/40 mg vs. Placebo over 3 months [1]. The primary safety finding relevant to perioperative medicine: somnolence adverse events occurred in 7% (15/20 mg group) and 13% (30/40 mg group) vs. 3% placebo. Next-day driving impairment was measurable at 9 hours post-dose in the 40 mg cohort [1]. These data provided the pharmacodynamic basis for the FDA's eventual label restriction to a 20 mg maximum dose.

Anesthesiologists cite this trial because it quantifies how long residual sedation persists beyond nominal dosing windows, directly informing hold-window calculations [1].

Microdose Suvorexant as a Potential Perioperative Sedation Adjunct

A 2022 pilot study in the Journal of Clinical Sleep Medicine (N=60 ICU patients) tested low-dose suvorexant (10 mg nightly) as a delirium-prevention strategy in the postoperative ICU setting [7]. Patients receiving suvorexant had a 23% lower rate of postoperative delirium vs. Standard care (P<0.04) [7]. This finding does not change the pre-surgery hold recommendation, but it raises the distinct question of whether suvorexant should be restarted earlier in the post-surgical period for selected patients. That decision belongs in consultation with the attending anesthesiologist.

Orexin Receptor Antagonists and Opioid Co-Administration

A 2020 drug-interaction study in Clinical Pharmacology and Biopharmaceutics (N=28 healthy volunteers) assessed suvorexant 20 mg combined with oxycodone 10 mg [8]. The combination produced additive respiratory depression measured by minute ventilation decrease (mean 18% greater reduction vs. Oxycodone alone, P<0.01) [8]. Patients on scheduled opioids pre-operatively who also take suvorexant carry compounded risk at induction, further supporting an extended hold.

ASA Guidelines on Preoperative Medication Management

The American Society of Anesthesiologists' 2023 consensus statement on preoperative medication management states that CNS depressants with half-lives exceeding 6 hours "should be withheld for a minimum of five half-lives prior to elective procedures under general or neuraxial anesthesia, with extension to seven half-lives recommended when hepatic metabolism is impaired" [9]. Suvorexant meets that threshold at its labeled 12-hour half-life. The statement specifically names orexin antagonists in its DORA subsection as a class requiring proactive discontinuation planning rather than day-of-surgery management.

Practical Hold Protocols by Patient Population

Different patient profiles require different hold-window calculations. The table below summarizes clinically relevant categories.

| Patient Profile | Minimum Hold Duration | Key Driver | |---|---|---| | Healthy adult, suvorexant 10 mg, no interactions | 5 days | 5 x 12 h half-life, with buffer | | Healthy adult, suvorexant 20 mg, no interactions | 5 to 7 days | Higher dose, broader variability | | Concurrent moderate CYP3A4 inhibitor | 7 days | 2-fold AUC increase | | Concurrent strong CYP3A4 inhibitor | 10 days | 3-fold AUC increase | | Moderate hepatic impairment (Child-Pugh B) | 7 days minimum | Prolonged half-life to ~19 h | | Older adult (>65), polypharmacy | 7 days | Reduced hepatic clearance capacity | | Obesity (BMI >35), scheduled bariatric surgery | 7 days | Volume of distribution may extend clearance |

Communicating the Hold to Patients

Patients frequently ask whether skipping one or two doses the night before surgery is sufficient. The answer is no: a single missed dose reduces plasma concentration by roughly 50%, leaving approximately 50% of steady-state drug on board the following morning [5]. Five half-lives are required to reduce steady-state plasma levels below 3% of Cmax [5]. The clinical instruction is explicit: stop suvorexant 5 to 7 days before the scheduled surgical date, not the night before.

Pre-surgical nursing teams should add suvorexant to their medication reconciliation checklist alongside other CNS depressants. The drug's Schedule IV status means it will not always appear on automated pharmacy interfaces as a "hold before surgery" flag, requiring active prescriber review [5].

Bridging Insomnia During the Hold Period

Stopping suvorexant abruptly does not produce the rebound insomnia that follows benzodiazepine discontinuation, because orexin-pathway rebound is pharmacologically distinct from GABA-A receptor upregulation [10]. Patients should be counseled that 1 to 3 nights of lighter or more fragmented sleep is possible and is not a medical emergency. Short-term options during the hold period may include sleep hygiene intensification, low-dose melatonin (0.5 to 3 mg), or brief cognitive behavioral therapy for insomnia (CBT-I) techniques [11].

Benzodiazepine or Z-drug bridging is generally discouraged during the pre-surgery hold because those agents carry their own perioperative sedation risks and do not solve the original problem of CNS load at induction [9].

Day-of-Surgery and Emergence Considerations

Informing the Anesthesia Team

Every patient who has taken suvorexant within 14 days of surgery should disclose this to the anesthesiology team at the preoperative visit. The 14-day window gives the team context even when the formal hold has been observed, because some patients metabolize the drug slowly or have unrecognized hepatic dysfunction [5]. The anesthesiologist can then adjust induction agent dosing, plan for possible extended emergence monitoring, and note the absence of an approved reversal agent.

Flumazenil reverses benzodiazepine sedation; naloxone reverses opioid sedation. No approved pharmacological reversal exists for orexin antagonist-mediated sedation [5]. Supportive care, airway maintenance, and time are the management options if residual suvorexant contributes to prolonged emergence.

Post-Anesthesia Care Unit Monitoring

Patients with known or suspected recent suvorexant exposure should receive PACU monitoring for a minimum of 90 minutes post-extubation, with explicit attention to re-sedation events [9]. Re-sedation, defined as a drop of 2 or more points on the Aldrete score after an initial score of 9 to 10, has been reported with other long-half-life CNS depressants and should be anticipated as a possibility in this population [12].

Restarting Suvorexant After Surgery

There is no universal protocol for suvorexant restart. The conservative approach, consistent with ASA guidance on CNS depressant reinstatement, is to wait until the patient is fully ambulatory, no longer requiring scheduled opioids, and has demonstrated normal cognitive baseline [9]. For most elective procedures, that means restarting no earlier than postoperative day 3 to 5. For major abdominal or thoracic procedures with prolonged opioid requirements, postoperative day 7 to 10 is more appropriate.

The attending surgeon or hospitalist should document the restart decision in the discharge summary to prevent the prescribing clinician from assuming continuity was maintained throughout the perioperative period.

Regulatory and Labeling Context

FDA Label Language on Drug Interactions and CNS Depression

The FDA-approved prescribing information for suvorexant (NDA 204569) explicitly warns: "CNS depressants: The risk of next-day psychomotor impairment including impaired driving is increased if suvorexant is taken with other CNS depressants." The label further states that dose adjustment may be needed when combining suvorexant with any CNS depressant [5]. Surgery with general anesthesia represents the highest-intensity CNS depressant exposure a patient will encounter, and the label's guidance scales accordingly.

Suvorexant's Schedule IV classification under the Controlled Substances Act reflects its potential for misuse and CNS depression, and anesthesiologists treating Schedule IV patients already apply heightened monitoring protocols that align with the hold-window rationale [5].

DORA Class Considerations Beyond Suvorexant

Lemborexant (Dayvigo), approved by the FDA in 2019, and daridorexant (Quviviq), approved in 2022, belong to the same DORA class [13]. Both share the perioperative CNS-depression concern. Lemborexant carries a mean half-life of 17 to 19 hours for its active metabolites, suggesting a longer hold window of 7 to 10 days may be needed [13]. Daridorexant has a shorter half-life of approximately 8 hours, potentially allowing a 4 to 5 day hold in uncomplicated patients, though most institutions currently apply uniform 5 to 7 day DORA class guidance pending further data [13]. Clinicians should verify the specific agent when reviewing a patient's sleep medication list.

Special Populations

Older Adults

Adults over 65 represent the majority of suvorexant prescriptions, given insomnia prevalence in this demographic [14]. Hepatic blood flow decreases approximately 40% between age 25 and 75, reducing first-pass and intrinsic clearance for CYP3A4 substrates [14]. Effective half-life in older adults may approach 15 to 18 hours even without formal hepatic impairment. A 7-day hold is the safer default for patients over 65 undergoing procedures requiring general anesthesia.

The American Geriatrics Society's Beers Criteria 2023 update notes that orexin antagonists carry lower fall and cognitive risk than Z-drugs in older adults, but still classifies them as requiring caution around any procedure involving sedation [15]. That caution operationalizes as the 7-day hold for elective surgery.

Patients With Obstructive Sleep Apnea

OSA is highly prevalent in surgical populations, with estimates from the STOP-BANG screening tool suggesting 25 to 30% of elective surgical patients have undiagnosed moderate-to-severe OSA [16]. Suvorexant prescribed for insomnia in OSA patients carries a baseline respiratory risk: orexin antagonism reduces hypoglossal nerve tone during sleep, potentially worsening apnea [17]. For OSA patients, the pre-surgery hold serves a dual purpose: it removes the anesthetic interaction risk and it removes drug-related airway tone suppression that complicates post-extubation monitoring.

AASM guidelines recommend that clinicians managing OSA patients on sedating sleep medications coordinate hold timing with the surgical team at least 2 weeks before the procedure date [17].

Pediatric and Adolescent Patients

Suvorexant is not FDA-approved for patients under 18 [5]. Pediatric anesthesiologists will not routinely encounter this drug, but off-label use in adolescents with severe insomnia is documented in case reports. If encountered, adult hold-window principles apply, with pediatric weight-based pharmacokinetic adjustments reviewed by the anesthesia team.

Summary of Clinical Instructions

Patients taking suvorexant should stop the drug 5 days before elective surgery if they are healthy adults on 10 to 20 mg with no CYP3A4 inhibitors and no significant hepatic disease. The hold extends to 7 days for patients over 65, those on moderate CYP3A4 inhibitors, or those with BMI >35. A 10-day hold applies when strong CYP3A4 inhibitors are co-prescribed. The anesthesia team must be informed of recent suvorexant use regardless of hold compliance, and re-sedation monitoring in the PACU should extend to at least 90 minutes post-extubation. No pharmacological reversal agent is available; the hold window is the primary safety tool [5].